Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx1 tHIVconsvX
- Development stage
- Phase 2
- Lead developer
- University of Oxford
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
ChAdOx1 tHIVconsvX is a replication-deficient chimpanzee adenovirus-vectored vaccine candidate designed for the prevention and treatment of HIV-1 infection. Developed through a collaboration involving the Jenner Institute at the University of Oxford and Ospedale San Raffaele, the vaccine utilizes the ChAdOx1 platform to deliver the tHIVconsvX immunogen. This immunogen is a second-generation trivalent mosaic consisting of highly conserved regions of the HIV-1 proteome, specifically segments from the Gag, Pol, Vif, and Env proteins. By targeting these functionally essential and mutationally constrained regions, the vaccine aims to elicit broad and potent T-cell immune responses capable of recognizing multiple global HIV-1 clades and preventing viral escape. It is frequently evaluated in heterologous prime-boost regimens, often in combination with the MVA tHIVconsvX vaccine.
- Other names
- ChAdOx1-tHIVconsvXChAdOx-1-tHIVconsvXChAdOx 1-tHIVconsvX
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Gag (HIV-1 Gag polyprotein)Human immunodeficiency virus type 1 reverse transcriptaseVif (HIV-1 Vif)
Beyond the preview
Go deeper on ChAdOx1 tHIVconsvX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx1 tHIVconsvX.